Nektar Therapeutics - Common Stock (NQ:NKTR)

46.99 -13.55 (-22.38%)

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	6,110,359
Open	55.40
Bid (Size)	47.10 (3,900)
Ask (Size)	47.37 (400)
Prev. Close	60.54
Today's Range	46.29 - 56.69
52wk Range	33.40 - 109.00
Shares Outstanding	183,801,441
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial ↗

Today 12:02 EDT

Nektar Therapeutics (NASDAQ:NKTR) presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to...

Via MarketBeat

Nektar (NKTR) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata.

Via The Motley Fool

Performance

YTD	+8.2%	+8.2%
1 Month	-34.2%	-34.2%
3 Month	-27.0%	-27.0%
6 Month	-37.9%	-37.9%
1 Year	-17.4%	-17.4%

More News

Nektar Therapeutics Q2 Earnings Call Highlights ↗

August 13, 2026

Via MarketBeat

NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q1 Earnings Beat Revenue Estimates but EPS Miss Drags Stock Lower ↗

May 07, 2026

Via Chartmill

Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call ↗

August 13, 2026

Via Benzinga

What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year ↗

June 24, 2026

Via The Motley Fool

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ↗

May 23, 2026

Via The Motley Fool

This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% ↗

May 23, 2026

Via The Motley Fool

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

Via The Motley Fool

Nektar Therapeutics Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Nektar (NKTR) Q1 2026 Earnings Transcript ↗

May 07, 2026

Via The Motley Fool

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR

May 05, 2026

From Pomerantz LLP

Via GlobeNewswire

NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th

May 04, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

May 04, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

May 04, 2026

From Schall Law

Via GlobeNewswire

NKTR DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR

April 30, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 30, 2026

From Schall Law

Via GlobeNewswire

NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT - Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

April 30, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR

April 28, 2026

From Pomerantz LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

April 28, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

April 27, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights

April 27, 2026

From Rosen Law Firm

Via Business Wire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 27, 2026

From Schall Law

Via GlobeNewswire

Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights

April 23, 2026

From Robbins LLP

Via Business Wire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

April 23, 2026

From Schall Law

Via GlobeNewswire

Frequently Asked Questions

Is Nektar Therapeutics - Common Stock publicly traded?

Yes, Nektar Therapeutics - Common Stock is publicly traded.

What exchange does Nektar Therapeutics - Common Stock trade on?

Nektar Therapeutics - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Nektar Therapeutics - Common Stock?

The ticker symbol for Nektar Therapeutics - Common Stock is NKTR on the Nasdaq Stock Market

What is the current price of Nektar Therapeutics - Common Stock?

The current price of Nektar Therapeutics - Common Stock is 46.99

When was Nektar Therapeutics - Common Stock last traded?

The last trade of Nektar Therapeutics - Common Stock was at 10/01/26 04:00 PM ET

What is the market capitalization of Nektar Therapeutics - Common Stock?

The market capitalization of Nektar Therapeutics - Common Stock is 8.64B

How many shares of Nektar Therapeutics - Common Stock are outstanding?

Nektar Therapeutics - Common Stock has 9B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.